
For patients who use biologic treatments for rheumatoid arthritis, specialty pharmacy care yields higher medication adherence and lower medical costs than retail pharmacy care.
For patients who use biologic treatments for rheumatoid arthritis, specialty pharmacy care yields higher medication adherence and lower medical costs than retail pharmacy care.
Adherence to drug therapy in hepatitis C increased total costs in year 1 relative to nonadherent patients, then decreased total costs in year 2.
This study evaluates the impact of patient cost sharing on the probability of receiving disease-modifying therapies and treatment compliance among patients with multiple sclerosis.
Specialty medications continue to proliferate, and their price tags to rise. How can payers and patients pay the bill?
Moving erlotinib from formulary tier 3 to tier 2 resulted in lower copayments and higher treatment persistence among lung cancer patients.
A decision-analytical model shows that everolimus has a favorable budget impact when introduced into the treatment algorithm for metastatic renal cell carcinoma.